Transaction

Clearwater advises Pharma Santé Développement on its debt restructuring and financing of Optipharm

Transaction

Pharma Santé Développement raised debt to refinance its existing debt and finance the acquisition of Optipharma

Debt Advisory

Undisclosed

Role

Adviser to PSD on its refinancing and the financing of Optipharma

Sector

Healthcare

Region

France

Clearwater has advised Pharma Santé Développement Groupe (PSD), an association for pharmacies on its debt restructuring and financing of pharmacy group, Optipharm.

Founded in 1998 and with over 1,000 members, Optipharm is an association for independent pharmacies that offer a range of benefits including a central purchasing system directly from laboratories, inventory services, training and support for pharmacists, and merchandising and layout stands for stores.

PSD is an integrated alliance of three sub-brands Pharma Santé Développement, NEP LA MARQUE and Pharmacade. With more than 1,300 pharmacy members and an accumulative turnover of €2.3bn, the group have a strong presence across France.

The group, headed by Philippe Besnard, brought Connect Pro, SofiPaca, Etoile Capital and Smalt Capital in 2018 with the ambition of becoming the major player for pharmacies.

This acquisition will enable PSD and Optipharm to become a leading pharmaceutical association with a combined membership of over 2,500 pharmacies.

image 139

This new acquisition is part of our consolidation strategy initiated in 2018. We are proud to contribute to the evolution of the French market by creating a leader capable of supporting its members in their future challenges.

Rémy Garrelo, Managing Director, Connect Pro
image 139

We are proud to have accompanied the group in this new phase, which is both structuring for PSD and for the pharmaceutical group market.

Alexandre Forget, Managing Partner, Clearwater

Advisers